Migraine and obesity, is there a link?

Giraud, P; Chauvet, Sylvie

doi:10.1016/j.neurol.2012.11.009

Cited by 7 publications

(4 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding suggests a possible role of β-endorphins in early extinction and in moderate intensity of headache side effect. The greater susceptibility to migraine, that people with obesity show, should also be taken into consideration [38].…”

Section: Discussionmentioning

confidence: 99%

Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity

et al. 2020

View full text Add to dashboard Cite

Purpose Repetitive Transcranial Magnetic Stimulation (rTMS) has been demonstrated to be effective in body weight control in individuals with obesity. Most clinical trials on rTMS provided a reassuring safety profile. In the present work, we present an extensive analysis on both severe and mild Adverse Events (AEs) in obese individuals treated with rTMS. Methods We examined the intensity, duration, correlation with the treatment, up to 1 year after the end of rTMS treatment. Results Descriptive analysis included a total of 63 subjects undergoing a 5-week deep rTMS experimental treatment for obesity (age 48.3 ± 10.4 years; BMI 36.3 ± 4.4 kg/m2): 31 patients were treated with high-frequency rTMS (HF), 13 with low-frequency rTMS (LF), and 19 were sham treated (Sham). Thirty-two subjects (50.8%) reported a total of 52 AEs, including mainly moderate (51.9%) events. The most frequently reported side effects were headaches of moderate intensity (40.4%) and local pain/discomfort (19.2%) and resulted significantly more frequent in HF group compared to other groups (p < 0.05). No significant differences among groups were found for the other reported AEs: drowsiness, insomnia, paresthesia, vasovagal reactions, hypertensive crisis. No AEs potentially related to the rTMS arised up to 1 year from the end of the treatment. Conclusions This is the first comprehensive safety analysis in obese patients treated with rTMS. The analysis did not reveal any unexpected safety concerns. Only headaches and local pain/discomfort have been significantly more frequent in the HF group, confirming the good tolerability of rTMS even in the obese population potentially more susceptible to side effects of brain stimulation.

show abstract

Section: Discussionmentioning

confidence: 99%

Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Studies in children have shown that the "elimination" or oligoantigenic diets with witch certain substances are excluded from consumption may be effective in migraine prophylaxis [37]. There is evidence that obesity may be associated with migraines, potentially through mechanisms involving adipose tissue inflammatory mediators [38,39], hence there is significant improvement in some patient groups who undergo weight loss programs [40]. Further dietary interventions may include a low-carbohydrate, high-fat ketogenic diet (KD) to help in migraine treatment.…”

Section: Dietmentioning

confidence: 99%

Non-Pharmacological Treatment of Primary Headaches—A Focused Review

Licina,

Radojicic,

Jeremic

et al. 2023

Brain Sciences

View full text Add to dashboard Cite

Headache disorders are a significant global health burden, leading to reduced quality of life. While vast pharmacological treatments are available, they may be associated with adverse effects or inadequate efficacy for some patients, therefore there is a need for exploring alternate treatment strategies. This review gives a brief explanation and evaluation of some established and emerging non-pharmacological approaches for headache management, focusing on nutraceuticals and diet, acupuncture, cognitive behavioral therapy (CBT), biofeedback, relaxation techniques, autogenic training, and neuromodulation. Special consideration is given to psychological interventions as they increase patient self-efficacy and provide strategies for managing chronic pain. Future research should focus on optimizing these therapies, identifying patient-specific factors influencing their effectiveness, and integrating them into holistic headache management strategies.

show abstract

“…Obesity seems to be a risk factor for migraine, [69][70][71][72] and obesity and weight gain contributes to worsening of migraine, with the potential of turning episodic migraine into chronic migraine. [73][74][75][76][77] Patients for COMICO were primarily recruited through the Danish Headache Center, which is a highly specialised unit and 38.2% turned out to have chronic migraine, which may have contributed to a higher BMI in this group.…”

Section: Body Mass Indexmentioning

confidence: 99%

Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO)

et al. 2020

View full text Add to dashboard Cite

PurposeMigraine has consistently been connected with rosacea. Commonalities in epidemiology, trigger factors and associated neuropeptides support shared aetiology and pathophysiological pathways, though underlying mechanisms remain unclear. We established two cohorts of patients diagnosed with either migraine and/or rosacea. All patients were phenotyped in regard to migraine and rosacea. In this article, we describe the baseline parameters of the cohorts. In the future, we expect that these cohorts will help uncover potential disease overlaps and allow for prolonged follow-up through national Danish health registers.ParticipantsCOpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO) are prospective cohorts based in the Capital region of Denmark. Participants for COROCO were recruited primarily through two tertiary dermatology clinics in Copenhagen, Denmark and patients for COMICO were recruited through a tertiary neurology clinic in Copenhagen, Denmark.Findings to dateCOROCO: 67.7% women (median age 51 years (interquartile range (IQR) 43.0–61.0)). Family history of migraine: 44.3%. Family history of rosacea: 45%. There were 13% who currently smoked, and 36.6% were former smokers. Regular intake of alcohol was present in 79.3% (median 4 items/week (IQR 1.0–9.0)). Median body mass index (BMI): 25.7 (IQR 23.1–29.0). Median Dermatology Life Quality Index (DLQI): 2 (IQR 1–5).COMICO: 88.5% women (median age 41 years (IQR 29.5–51.0)). Family history of migraine: 73.4%. Family history of rosacea: 18.4%. There were 17.1% who currently smoked, and 26.0% former smokers. Regular intake of alcohol was present in 62.2% (median intake: 2 item/week (IQR 1.0–3.0)). Median BMI was 24.6 (IQR 21.5–28.2). Median DLQI was 1 (IQR 0–2).Future plansCOROCO and COMICO serve as strong data sources that will be used for future studies on rosacea and migraine with focus on risk factors, occurrence, treatment, natural history, complications, comorbidities and prognosis.Trial registration numberClinicalTrials.gov Registry (NCT03872050).

show abstract

Migraine and obesity, is there a link?

Cited by 7 publications

References 30 publications

Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity

Safety and tolerability of repeated sessions of deep transcranial magnetic stimulation in obesity

Non-Pharmacological Treatment of Primary Headaches—A Focused Review

Cohort profile: COpenhagen ROsacea COhort (COROCO) and COpenhagen MIgraine COhort (COMICO)

Contact Info

Product

Resources

About